Top

Clinical and Translational Oncology

Published in:

01-09-2013 | Brief Research Article

Clinical target volume definition for glioblastoma radiotherapy planning: magnetic resonance imaging and computed tomography

Authors: A. Fiorentino, R. Caivano, P. Pedicini, V. Fusco

Published in: Clinical and Translational Oncology | Issue 9/2013

Abstract

Purpose

To assess the differences between the target delineation using computed tomography (CT) and imaging fusion CT/magnetic resonance imaging (MRI) for the radiotherapy planning of glioblastoma.

Methods

One hundred-twenty gross tumor volume and clinical target volume on CT and MRI (GTV_CT/CTV_CT, GTV_MRI/CTV_MRI, respectively) were contoured and evaluated. The treatments planning (total dose 60 Gy) based on CTV_CT were analysed in terms of percentage of CTV_CT and CTV_MRI receiving 95 % of the prescribed dose (V₉₅-CTV_CT, V₉₅-CTV_MRI).

Results

GTVs and CTVs contoured on MRI were significantly larger than those delineated on CT (p = 0.0003, p = 0.0006, respectively). Nighty-two percent of CTV_CT was coincident with the CTV_MRI and 8 % was normal tissue; 20 % of CTV_MRI, considered as tumor volume, was not included on CTV_CT. The V₉₅-CTV_MRI was significantly lower than the V₉₅-CTV_CT (p = 0.0005).

Conclusions

In the delineation of glioblastoma target volume, fusion CT/MRI was preferred. The CT only is insufficient for the CTV dose coverage.

Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466PubMedCrossRef

Balducci M, Chiesa S, Diletto B et al (2012) Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study. Neuro Oncol 14(1):79–86PubMedCrossRef

Balducci M, Apicella G, Manfrida S et al (2010) Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high grade gliomas. Strahlen Onkol 186(10):558–564CrossRef

Baumert BG, Brada M, Bernier J et al (2008) EORTC 22972–26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality assurance results of the stereotactic boost arm. Radiother Oncol 88:163–172PubMedCrossRef

Balducci M, Fiorentino A, De Bonis P et al (2012) Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. Med Oncol 29(5):3478–3483. doi:10.1007/s12032-012-0263-3

Chan JL, Lee SW, Fraass BA et al (2002) Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635–1642PubMedCrossRef

Aydin H, Sillenberg I, von Lieven H (2001) Patterns of failure following CT-based 3-D irradiation for malignant glioma. Strahlenther Onkol 177:424–431PubMedCrossRef

Chang EL, Akyurek S, Avalos T et al (2007) Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 68:144–150PubMedCrossRef

Oppitz U, Maessen D, Zunterer H, Richter S, Flentje M (1999) 3-D recurrence patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 53:53–57PubMedCrossRef

10.

Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911PubMedCrossRef

11.

Farace P, Giri MG, Meliadò G et al (2011) Clinical target volume delineation in glioblastomas: pre-operative versus post-operative/pre-radiotherapy MRI. British J Radiol 84:271–278CrossRef

12.

Weber DC, Wangi H, Albrecht S et al (2008) Open low-field magnetic resonance imaging for target definition, dose calculation and set-up verification during three-dimensional CRT fo glioblastoma multiform. Clin Oncol 20:157–167CrossRef

13.

Krempien RC, Schubert K, Zierhut D et al (2002) Open low-field magnetic resonance imaging in radiation therapy treatment planning. Int J Radiat Oncol Biol Phys 53:1350–1360PubMedCrossRef

14.

Thornton AF Jr, Sandler HM, Ten Haken RK et al (1992) The clinical utility of magnetic resonance imaging in 3-dimensional treatment planning of brain neoplasms. Int J Radiat Oncol Biol Phys 24:767–775PubMedCrossRef

15.

Just M, Rosler HP, Higer HP et al (1991) MRI-assisted radiation therapy planning of brain tumors clinical experiences in 17 patients. Magn Reson Imaging 9:173–177PubMedCrossRef

16.

Lawrence YR, Li XA, el Naqa I et al (2010) Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 76(3 Suppl):S20–S27PubMedCrossRef

17.

Halperin EC, Bentel G, Heinz ER, Burger PC (1989) Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys 17:1347–1350PubMedCrossRef

18.

Minniti G, Amelio D, Amichetti M et al (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97(3):377–381PubMedCrossRef

19.

Lattanzi JP, Fein DA, McNeeley SW et al (1997) Computed tomography-magnetic resonance image fusion: a clinical evaluation of an innovative approach for improved tumor localization in primary central nervous system lesions. Radiat Oncol Investig 5:195–205PubMedCrossRef

20.

Myrianthopoulos LC, Vijayakumar S, Spelbring DR et al (1992) Quantitation of treatment volumes from CT and MRI in high grade gliomas: implications for radiotherapy. Magn Reson Imaging 10:375–383PubMedCrossRef

Title: Clinical target volume definition for glioblastoma radiotherapy planning: magnetic resonance imaging and computed tomography
Authors: A. Fiorentino
R. Caivano
P. Pedicini
V. Fusco
Publication date: 01-09-2013
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 9/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0992-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2013

Management of malignant insulinoma

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung

Beam angle selection for intensity-modulated radiotherapy (IMRT) treatment of unresectable pancreatic cancer: are noncoplanar beam angles necessary?

Proteomic biomarkers in lung cancer

Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer